2nd Edition of International Summit on Hematology and Blood Disorders
June 05-07, 2025
Rare Hematologic Diseases
A rare disease in the United States is one that affects fewer than 200,000 people in the country. Congress established this definition in the Orphan Drug Act of 1983. Because pharma corporations were not interested in developing medicines for rare diseases, they became known as orphan diseases. The Orphan Drug Act established financial incentives for companies to discover new medicines for uncommon diseases. The definition of rare disease was required in order to determine which disorders would be eligible for the new incentive programmes. Certain cell types can be created in abnormally large quantities or in atypical forms when the usual process of blood cell growth and development breaks down. Blood malignancies and other blood problems arise as a result of this.
Jie Xu
The University of Texas MD Anderson Cancer Center, United States
Ravishankar Rao Baikady
The Royal Marsden NHS Foundation Trust, United Kingdom
Peter J Van Der Spek
Erasmus University Medical Center, Netherlands
Aida I Richardson
Ann & Robert H. Lurie Children's Hospital of Chicago, United States
Maryam Asif
University of Washington, United States
Raykina Elena
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Russian Federation
Santosh Kumar Mondal
Department of Pathology and Laboratory Medicine AIIMS, IndiaSubmit your abstract Today
Title : Single cell multi-omics in PBMC’s
Peter J Van Der Spek, Erasmus University Medical Center, Netherlands
Title : Myeloid neoplasms and molecular genetic alterations (Germline vs Somatic) that characterize specific entities in pediatric patients
Aida I Richardson, Ann & Robert H. Lurie Children's Hospital of Chicago, United States
Title : Overview of 2021 guidelines on the diagnosis of Von Willebrand Disease (VWD)
Maryam Asif, University of Washington, United States
Title : Clonal evolution in children with inherited bone marrow failure syndromes
Raykina Elena, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Russian Federation
Title : Defining the clinical contribution of platelet-derived FXIII-A to regulation of fibrinolysis
Fahad S Alshehri, King Faisal Medical City for Southern Region, Saudi Arabia
Title : Multiple alloantibodies: The strategy for identifying antibodies and transfusion management
Ahmed Alharbi, King Abdulaziz Medical City, Saudi Arabia